title: Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study.
abstract: The PANCOSTABRAX study evaluated the cost-effectiveness of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine (GEM) versus GEM alone in the treatment of patients with metastatic pancreatic cancer in Spain. Efficacy data were obtained from the MPACT study and were modeled to a lifetime horizon using a Markov model. The analysis was performed from the payer's perspective. Use of resources and key assumptions of the analysis were validated by a panel of oncologists. The addition of nab-paclitaxel to GEM showed higher effectiveness results (0.156 additional quality adjusted life years) at a higher cost (€6,477), resulting in a cost per quality-adjusted life years gained of €41,519. The combination of nab-paclitaxel and GEM has been shown to be an effective and well-tolerated option for the treatment of metastatic pancreatic cancer and, in addition to becoming the new standard of care, could also be considered a cost-effective option.
authors.affiliation: Hospital Universitario Ramón y Cajal, Madrid, Spain.
authors.forename: Alfredo
authors.initials: A
authors.lastname: Carrato
authors.forename: Pilar
authors.initials: P
authors.lastname: García
authors.forename: Rafael
authors.initials: R
authors.lastname: López
authors.forename: Teresa
authors.initials: T
authors.lastname: Macarulla
authors.forename: Fernando
authors.initials: F
authors.lastname: Rivera
authors.forename: Javier
authors.initials: J
authors.lastname: Sastre
authors.forename: Joana
authors.initials: J
authors.lastname: Gostkorzewicz
authors.forename: Patricia
authors.initials: P
authors.lastname: Benedit
authors.forename: Ferran
authors.initials: F
authors.lastname: Pérez-Alcántara
mesh_terms: D000418:Albumins / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D008390:Markov Chains; D018803:Models, Economic; D009362:Neoplasm Metastasis; D017239:Paclitaxel / Q000008:administration & dosage; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000191:economics / Q000473:pathology; D019057:Quality-Adjusted Life Years; D013030:Spain; D000093542:Gemcitabine
chemical_list: C520255:130-nm albumin-bound paclitaxel; D000418:Albumins; D003841:Deoxycytidine; D017239:Paclitaxel; D000093542:Gemcitabine
keywords: Spain; cancer; cost; nab-paclitaxel; pancreatic